Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

10.48 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 Next >
Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
From Kashiv BioSciences, LLC and Amneal Pharmaceuticals, Inc. and Alvotech and Advanz Pharma
Via Business Wire
Amneal to Report Third Quarter 2025 Results on October 30, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segment 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
Expands Amneal’s Affordable Medicines portfolio and broadens patient access 
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Reports Second Quarter 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal to Report Second Quarter 2025 Results on August 5, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal to Participate at Upcoming Investor Conferences in June
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Amneal Reports First Quarter 2025 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report First Quarter 2025 Results on May 2, 2025
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at Upcoming Investor Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at Upcoming Investor Conferences
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Reports Third Quarter 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.